About the Company
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XENE News
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event. Company Fireside Chat ...
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
Xenon Pharmaceuticals Inc (NASDAQ:XENE), a clinical-stage biopharmaceutical company, focuses on developing therapeutics to ...
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Xenon (XENE – Research Report) on March 1 and set a price target of ...
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off
Vancouver’s life sciences scene dates to the first biotech boom in the early 1980s. Toronto and Montreal also produced ...
Buy Rating Affirmed: Longboard Pharmaceuticals’ Bexicaserin Shows Promising Efficacy and Strategic Milestones
Citi analyst David Hoang maintained a Buy rating on Longboard Pharmaceuticals (LBPH – Research Report) yesterday and set a price target ...
Marinus Pharmaceuticals: Q4 Earnings Snapshot
The Radnor, Pennsylvania-based company said it had a loss of 74 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Loading the latest forecasts...